Level C· Early human research exploring benefitsRetrospective StudyPubMedOpen access

Intra-articular administration of autologous adipose-derived stem cells in hip osteoarthritis: Longitudinal treatment trajectories and prognostic factors.

Hatano M., Ishikura H., Terao T., Kasai T., Yamagami R., Higuchi J.

Retrospective Study with a reported sample of 129 on Osteoarthritis, Ligament Injury, Hip Osteoarthritis, published in Regen Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Regen Ther (2025)
Country
Netherlands
Reported sample size
129
Source database
PubMed
PMID
40225053
PMCID
PMC11992404
DOI
10.1016/j.reth.2025.03.010
Citations
1

Abstract (original English)

Introduction Evidence regarding the effectiveness of mesenchymal stem cells in improving hip function in patients with hip osteoarthritis (OA) remains inconsistent. Therefore, we aimed to estimate the longitudinal trajectories of treatment effects in individuals with hip OA following intra-articular administration of autologous adipose-derived stem cells (ASCs), both in the overall cohort and the cohort stratified by OA severity, and to explore the prognostic factors of treatment outcomes. Methods This retrospective study included adults with hip OA who underwent magnetic resonance imaging (MRI) before treatment between 2020 and 2023. All patients underwent intra-articular ASC administration. The primary outcomes were the total scores on the Japanese Orthopaedic Association Hip Disease Evaluation Questionnaire (JHEQ) at 1, 3, and 6 months after treatment. A linear mixed-effects model was used to estimate the marginally predicted JHEQ total score changes over time for all patients and compare these changes among subgroups categorized according to OA severity. Furthermore, models that included MRI findings were used to explore potential prognostic factors. Results We identified 168 hips in 129 patients. In the analysis of all patients, the JHEQ total scores significantly increased at 1, 3, and 6 months after treatment compared with baseline. In the mixed-effects analysis, the pre

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research